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Abstract: 
Hyperkalemia is common in patients with heart failure or chronic kidney disease, particularly 
those taking renin–angiotensin–aldosterone system inhibitors, and can cause arrhythmias and 
sudden cardiac death. The most widely used treatment, sodium polystyrene sulfonate (SPS), 
limits gastrointestinal potassium absorption, but has poor palatability. RDX7675 
(RDX227675) is the calcium salt of a re-engineered polystyrene sulfonate-based resin, with 
improved palatability over SPS. The pharmacodynamic effects and safety of RDX7675 were 
assessed in a phase 1, single-center, randomized, active-controlled study. Healthy volunteers 
received nominal active doses of RDX7675 4.6 g b.i.d., 4.6 g t.i.d., 6.9 g b.i.d., 13.7 g q.d., 
9.2 g t.i.d., or 13.7 g b.i.d. (n = 12 each), or equivalent doses of SPS (n = 3 each), for 4 days. 
RDX7675 dosing increased stool potassium excretion and decreased urinary potassium 
excretion from baseline. Stool potassium excretion increased by up to 1481 mg/day with 
RDX7675 (6.9 g b.i.d.), and urinary potassium excretion decreased by up to 939 mg/day 
(13.7 g b.i.d.). Similar levels of potassium excretion were observed using q.d., b.i.d., or t.i.d. 
dosing of a 13.7 g total daily RDX7675 dose. Few adverse events were reported. In 
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conclusion, repeated oral dosing with RDX7675 over 4 days reduced potassium absorption in 
healthy volunteers; the results support q.d. dosing of RDX7675 in future clinical studies. 
Keywords: RDX7675, RDX227675, sodium polystyrene sulfonate, potassium binder, 
pharmacodynamics, hyperkalemia 
Introduction 
Hyperkalemia, an elevated level of serum potassium, is a potentially life-threatening 
condition with consequences that can include cardiac arrhythmias and sudden cardiac death.
1
 
The condition is often defined as a serum potassium concentration of at least 5.0 or 
5.5 mmol/L, and mortality risk increases with rising serum potassium concentrations above 
5.0 mmol/L.
2-4
 However, levels above these thresholds do not affect all patients in the same 
manner.
4,5
 Only one half of patients with serum potassium above 6.5 mmol/L demonstrate 
electrocardiographic changes and there is no defined threshold above which hyperkalemia 
distinctly causes adverse events or death, because the risk depends in part on the rate of rise 
of serum potassium, as well as pH, concomitant cardiovascular medications and 
comorbidities.
4-6
 Typical symptoms of hyperkalemia may include fatigue, muscle weakness, 
heart palpitations, nausea, vomiting, chest pain, and paresthesia. However, hyperkalemia is 





Hyperkalemia most commonly develops in patients older than 65 years and with comorbid 
conditions, such as chronic kidney disease (CKD), heart failure, or diabetes.
3,4,8
 In patients 
with CKD, hyperkalemia can occur through a decreased glomerular filtration rate and mild 
acidosis, which limit renal excretion of potassium.
3,4
 A cross-sectional study of pre-dialysis 
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patients with advanced CKD reported a prevalence of hyperkalemia of 32% (serum 
potassium ≥5.5 mmol/L),
9
 while a study monitoring patients undergoing maintenance dialysis 
found that 12.5% had a 3-month-average serum potassium level above 5.5 mmol/L.
10
 
Treatment guidelines for patients with CKD and heart failure recommend renin–angiotensin–
aldosterone system (RAAS) inhibitors as a first-line therapy to improve renal and 
cardiovascular outcomes and thus reduce morbidity and mortality.
11-13
 However, RAAS 
inhibitors decrease kidney excretion of potassium through their inhibitory effect on 
aldosterone, which can exacerbate hyperkalemia risk in patients with CKD, diabetes, and/or 
heart failure because of certain physiological disturbances associated with these conditions, 
such as aldosterone deficiency, decreased delivery of sodium to the distal nephron, and 
abnormal functioning of the cortical collecting tubule.
14
 Concern over the development of 
hyperkalemia in patients with CKD and/or heart failure can lead to RAAS inhibitor dose 
reduction and discontinuation, which increases cardiovascular risk.
8,15
 There is, therefore, a 
need for agents that can help manage or prevent hyperkalemia in the long term and thereby 
enable concomitant use of optimal RAAS inhibitor therapy.  
 
Orally administered cation exchange resins have been the dominant mode of treatment for 
acute or episodic hyperkalemia for more than 60 years. These compounds reduce potassium 
absorption by sequestering potassium in the gastrointestinal tract, thereby increasing 





, the latter not marketed in the USA) is one of the most widely used potassium 
binders, and was first approved by the US Food and Drug Administration (FDA) in 1958.
18
 
However, SPS has several limitations that make it unsuitable as a long-term therapy for 
hyperkalemia. First, the sodium counter-exchange ion of SPS increases the dietary sodium 
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intake of patients taking this medication, which negatively impacts the RAAS
19
 and is 
believed to limit responsiveness to RAAS inhibition.
20
 Indeed, excessive sodium intake 
counteracts the dietary salt restriction recommended in patients with CKD and/or heart failure 
taking RAAS inhibitors.
21,22
 Secondly, SPS consists of hard, irregularly shaped, shard-like 
particles that give it a gritty texture in the mouth, which, together with its unpleasant taste, 
reduces palatability and is therefore likely to reduce adherence in a long-term setting. 
Individuals with CKD and/or heart failure are prescribed multiple medications to take at 
various times of the day, making palatability particularly important for facilitating long-term 
medication use. Thirdly, to alleviate its constipating effect, SPS is sometimes used in 
combination with sorbitol. In September 2009, the FDA recommended against the 
concomitant use of sorbitol with SPS as a result of reported cases of colonic necrosis and 
other severe gastrointestinal side effects (although such effects are rare).
23
 The precise 
mechanism is unknown; however, it has been postulated that sorbitol, rather than SPS, may 
be the cause.
24
 In addition to the aforementioned limitations, SPS was approved over 50 years 
ago and has not undergone testing in accordance with current regulatory standards, although 




RDX7675 (Supplemental Figure S1), also known as RDX227675, is a novel potassium-
binding agent in development for the treatment of hyperkalemia. It is the calcium salt of a 
polystyrene sulfonate resin that has been re-engineered to improve potassium-binding 
efficiency compared with SPS
25
 and overcome many of the latter’s undesirable aspects. For 
example, the RDX7675 resin comprises smooth, spherical, malleable beads with a relatively 
narrow size range (80% with diameter 14–52 µm; SPS, 11–124 µm; both measured using wet 
dispersion laser diffraction), giving it improved texture, taste, and overall palatability 
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compared with the gritty shard-like particles of SPS.
26
 Indeed, a palatability study conducted 
in healthy volunteers showed that RDX7675 had a higher rate of overall acceptability in the 
mouth compared with SPS.
26
 RDX7675 may therefore be more acceptable to patients than 
SPS for long-term use, particularly given that the recommended dosage for SPS requires up 
to four daily administrations.
16
 Importantly, RDX7675 also has a calcium rather than sodium 
counter-exchange ion, so its administration does not increase dietary sodium intake. 
Moreover, RDX7675 is not intended to be taken with sorbitol, thereby avoiding the potential 
for sorbitol-related gastrointestinal side effects. RDX7675 is insoluble in aqueous solutions 
and is not absorbed from the gastrointestinal tract, which also minimizes the potential for off-
target side effects. In preclinical studies in mice, RDX7675 administration has been found to 




The aim of the phase 1, single-center, randomized, active-controlled study in healthy 
volunteers reported here was to investigate the pharmacodynamic effects and safety of 
different dosing regimens of RDX7675 in humans. 
Methods 
Study Overview 
The study protocol and other documentation for this phase 1, single-center, randomized, 
active-controlled study, conducted at Quotient Clinical (Nottingham, UK), were approved by 
the Wales Research Ethics Committee (Cardiff, UK) before the study began. All volunteers 
provided written informed consent, and the study was conducted in accordance with 
International Conference on Harmonisation Good Clinical Practice guidelines and with the 
Declaration of Helsinki and its amendments. The study evaluated the relative safety and 
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tolerability of RDX7675 compared with SPS, and determined the pharmacodynamics of 
different oral dose regimens of RDX7675. 
Study Participants 
Healthy men and women aged 18–65 years with a body mass index of 18–32 kg/m
2
 were 
eligible to participate. From 24 hours before admission up until discharge from the study, 
volunteers were required to abstain from the following: alcohol; food likely to disturb 
gastrointestinal transit, such as spicy, high-fat, or high-fiber foods; and liquids or food 
containing grapefruit, cranberry, caffeine, or other xanthines. In addition, volunteers were 
required to abstain from food containing poppy seeds from 48 hours before admission until 
discharge from the study, and from unaccustomed strenuous exercise for 72 hours before the 
screening visit and then from 72 hours before admission until discharge from the study.  
 
Key exclusion criteria were: a history of hypokalemia, hypomagnesia, or hypercalcemia; 
serum potassium below the lower limit of normal (<3.5 mmol/L) at baseline (day −2); an 
allergy or history of sensitivity to SPS; use of treatments or supplements that are known to 
affect stool consistency or gastrointestinal motility, including fiber supplements, probiotic 
medications or supplements, antidiarrheals, prokinetic drugs, and enemas, in the week before 
admission; and use of salt or electrolyte supplements containing sodium, potassium, chloride, 
or bicarbonate formulations in the week before admission. 
Study Design 
Volunteers attended a screening visit up to 28 days before the first dose of study drug to 
confirm eligibility for the study. Eligible participants were admitted to the clinical unit in the 
evening 3 days before the first dose (day −3). On the morning of day 1, volunteers were 
randomly assigned using a computer-generated randomization schedule to 4 days of 
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treatment with either RDX7675 or SPS in a 4:1 ratio, divided into cohorts with different 
dosing regimens to explore the relative efficacies of once-daily (q.d.), twice-daily (b.i.d.), and 
three times daily (t.i.d.) dosing (Table 1). The nominal active doses of each agent were 
determined following adjustment for counter-exchange ion content. Hereafter, unless 
otherwise stated, all regimens are given in terms of the nominal active dose, and data are 
presented in order of increasing total daily dose rather than the order in which the regimens 
were evaluated. 
 
Within each cohort, volunteers received either a synthetic vanilla-flavored jelly-like 
formulation of RDX7675 (prepared in water thickened with 1% xanthan gum) or the 
corresponding doses of water-reconstituted SPS (Resonium A, vanilla flavor) as an active 
comparator. The recommended starting dose of SPS is a mass of 15 g taken three or four 
times per day,
16
 and based on preclinical data
25
 it was anticipated that the therapeutic dose of 
RDX7675 would be similar. As this was the first swallowed dose of this RDX7675 
formulation given to humans, a comparatively low starting dose of 4.6 g t.i.d. was selected. 
Following completion of dosing in each regimen group, there was an interim review of the 
available safety and pharmacodynamic data in order to select the dose level of RDX7675 and 
SPS for the next cohort. The maximum total daily dose of RDX7675 used in this study, 27.5 
g, was lower than the aforementioned recommended starting dose of SPS. 
 
Volunteers were given their assigned dose of RDX7675 or SPS approximately 30 minutes 
after starting meals. Timings were approximately 08:00 for q.d. dosing, 08:00 and 18:00 for 
b.i.d. dosing, and 08:00, 13:00, and 18:00 for t.i.d. dosing. Discharge was on day 5, and a 
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follow-up visit took place 2–5 days later (day 7–10). Volunteers received the same 
meals/snacks in the same order on the same days while in the study center. Their diet was 
standardized for potassium content throughout the 4-day treatment period and the 2-day 
baseline period (i.e. days −1 and −2). 
Study Assessments 
Pharmacodynamic assessments included stool potassium, sodium, calcium, phosphorus, and 
magnesium content, and urinary potassium content, assessed over each 24-hour interval from 
day −2 to day 4. Time to first bowel movement, stool frequency, stool consistency (as 
measured by the Bristol Stool Form Scale [BSFS]),
27
 stool weight, and ease of passage were 
assessed from day −2 to day 4. Safety assessments were performed at regular intervals and 
included physical examinations, clinical laboratory evaluations (hematology, clinical 
chemistry, urinalysis), vital signs, and electrocardiograms. Adverse events (AEs) were 
monitored throughout the study. 
Analytical Methods 
Electrolyte content of stool samples were determined by RTI International (Durham, NC, 
USA) using methodology previously described.
28
 The potassium content of urine samples 
was determined by The Doctors Laboratory (London, UK) using ion-selective electrode 
measurements obtained by standard clinical laboratory techniques (Consolidated Medical 
Bio-Analysis, Cypress, CA, USA). 
Statistical Analyses 
No formal statistical analysis was performed. For the pharmacodynamic assessments 
(electrolyte excretion and stool parameters), descriptive statistics are presented. Baseline 
values for each analysis were calculated as the average of day −2 and day −1. Only those 
participants who had sufficient urine and stool sampling data for pharmacodynamic 
parameter estimation were included in the pharmacodynamic population dataset. For the 
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safety assessments, descriptive statistics are presented. All volunteers who received at least 
one dose of study medication were included in the safety analysis dataset.  
 
No formal sample size calculation was performed for this exploratory study. A sample size of 
15 individuals per cohort (12 given investigational drug [RDX7675] and 3 given active 
comparator [SPS]) is typical for phase 1 studies of this type and was expected to provide a 
sufficient number of observations to meet the objectives of the study. 
Results 
Baseline Characteristics 
A total of 91 volunteers were enrolled into the six dose cohorts, of whom 90 completed the 
study (per cohort: RDX7675, n = 12; SPS, n = 3). There were no notable differences in 
demographic characteristics between individuals assigned to RDX7675 or SPS (Table 2) or 
between the regimens. One volunteer in the 13.7 g q.d. cohort withdrew on day 1 having 
failed to swallow the given RDX7675 dose and with only baseline data recorded. This 
individual was included in the safety population, and a replacement volunteer was enrolled. 
Pharmacodynamics: Stool and Urinary Potassium Excretion 
Repeated dosing of RDX7675 or SPS over 4 days resulted in increased stool potassium 
excretion throughout the treatment period, with concomitant reductions in urinary potassium 
excretion. Mean increases in daily stool potassium from baseline were as high as 1481 mg 
(6.9 g b.i.d.), with decreases in daily urinary potassium of up to 939 mg (13.7 g b.i.d.) in the 
RDX7675 cohorts (Figure 1). Changes of a similar magnitude were generally observed in the 
SPS cohorts (Supplemental Figure S2). Stool potassium levels increased, and urinary 
potassium levels decreased, from baseline with increasing total daily RDX7675 dose over the 
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4 day period, although this effect was less apparent after day 3 for the highest RDX7675 dose 
evaluated (27.5 g, i.e. 9.2 g t.i.d. and 13.7 g b.i.d.; Figure 1). Over 4 days, similar levels of 
potassium excretion were observed using q.d., b.i.d., and t.i.d. dosing of a 13.7 g total daily 
RDX7675 dose (Figure 1). 
Pharmacodynamics: Excretion of Other Electrolytes in Stool  
Excretion of other electrolytes in stool was highly variable, as expected. Volunteers taking 
RDX7675 generally had increased stool sodium and calcium excretion with no consistent 
effects on stool phosphorus or magnesium excretion (Table 3). 
Pharmacodynamics: Stool Parameters 
Data for stool frequency, stool consistency, ease of passage, and stool weight at baseline and 
on day 4 for volunteers who received RDX7675 are presented in Table 4. In general, on day 4 
of treatment, there were increases from baseline in stool frequency and stool weight 
following dosing with RDX7675 or SPS. Mean baseline stool frequency in the RDX7675 
cohorts ranged from 1.0 to 1.2 bowel movements/day, which increased to between 1.3 and 
1.6 bowel movements/day after 4 days of dosing. Mean baseline stool weight with RDX7675 
ranged from 70 g/day to 140 g/day, increasing to between 136 g/day and 324 g/day on day 4. 
There were no overall trends in stool consistency (BSFS score) or ease of passage between 
baseline and day 4 with either RDX7675 or SPS. Mean BSFS score with RDX7675 ranged 
from 2.7 to 4.0 at baseline, and from 2.3 to 4.6 on day 4. Ease of passage with RDX7675 
ranged between 3 (straining needed) and 4 (normal) throughout the monitoring period.  
Safety 
Both RDX7675 and SPS were generally well tolerated during repeated dosing for 4 days, 
with few AEs reported across all dosing regimens. The proportion of volunteers reporting 
AEs was similar with RDX7675 and SPS, with 24 of 73 and 6 of 18 volunteers reporting at 
least one AE after dosing with RDX7675 or SPS, respectively (Table 5). The number of 
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volunteers reporting at least one AE was highest following dosing with RDX7675 9.2 g t.i.d. 
(10/12), 13.7 g b.i.d. (5/12), and 4.6 g t.i.d. (4/12). There was no apparent difference in the 
incidence of AEs between the other RDX7675 regimens, or between the different SPS 
regimens. The most common AEs were gastrointestinal in nature, most frequently 
constipation, abdominal pain, and nausea. Although most AEs were mild in severity, a small 
number of AEs were of moderate intensity. Of the six moderate AEs experienced by 
volunteers receiving RDX7675, four were gastrointestinal in nature (nausea, constipation, 
and lower abdominal pain), all in the RDX7675 9.2 g t.i.d. cohort. The most frequently 
reported treatment-related AEs were also gastrointestinal in nature (Table 5). The highest 
incidence of these treatment-related AEs occurred at the highest RDX7675 dose levels, 9.2 g 
t.i.d. and 13.7 g b.i.d., while there were no treatment-related AEs in the RDX7675 6.9 g b.i.d. 
or 13.7 g q.d. cohorts. There were no serious or severe AEs during the study; however, one 
volunteer in the RDX7675 9.2 g t.i.d. cohort had treatment withdrawn as a result of moderate 
nausea (considered to be possibly treatment-related). There were no clinically significant 
findings in clinical laboratory assessments, including serum potassium, sodium, calcium, 
chloride or bicarbonate (Supplemental Table S1), as well as vital signs, electrocardiograms, 
or physical examinations. 
Discussion 
Treatment guidelines for patients with CKD and/or heart failure recommend the use of RAAS 
inhibitors,
11-13
 which can increase the risk of hyperkalemia.
3
 There is, therefore, a need for 
hyperkalemia therapies that can be used concomitantly with RAAS inhibitors over extended 
periods of time. Cation exchange resins that reduce potassium absorption from the gut have 
been used to treat hyperkalemia since the 1950s, with SPS being the most widely used of 
these medications. However, poor palatability and the potential for gastrointestinal side 
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effects have limited the use of SPS as a long-term treatment.
8,18
 In recent years, new 
treatments for patients with hyperkalemia have been developed. Patiromer (Veltassa
®
), 
approved for use in the USA and Europe, reduced serum potassium levels in short-term 
clinical trials in patients with hyperkalemia and CKD or heart failure,
29,30
 and in a long-term 
study in patients with hyperkalemia and diabetic nephropathy.
30
 Sodium zirconium 
cyclosilicate (ZS-9), which exchanges potassium for sodium ions, has been shown in two 
large phase 3 trials to lower serum potassium levels in a broad cross-section of patients with 
hyperkalemia.
31,32
 Patiromer has been associated with gastrointestinal adverse effects, 





RDX7675, the calcium salt of a re-engineered polystyrene sulfonate-based resin, is a 
potassium binding agent that is being developed as a treatment for patients with 
hyperkalemia. Its novel design and formulation result in smooth, spherical, malleable beads 
with a relatively narrow size range (80% with diameter 14–52 µm; SPS, 11–124 µm) for 
enhanced mouth-feel and palatability, shown in a healthy volunteer study to have improved 
acceptability compared with SPS.
26
 The use of calcium rather than sodium as the counter-
exchange ion, and administration without sorbitol or other cathartics, aligns with best clinical 
practice.
22,23
 The aim of the present study was to generate clinical data on the ability of 
several dosing regimens of RDX7675 to reduce potassium absorption, and their safety and 
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In this study, repeated oral dosing with RDX7675 q.d., b.i.d., or t.i.d. over 4 days reduced 
potassium absorption, as shown by increases from baseline in stool potassium excretion with 
concomitant decreases in urinary potassium. The increases in daily stool potassium excretion 
observed after 4 days of RDX7675 administration (844–1481 mg in volunteers given total 
daily doses of 9.2–13.7 g) were of similar magnitude to those observed in a healthy volunteer 
study of patiromer (617–1929 mg in volunteers given total daily doses of 12.6–50.4 g [4.2–
16.8 g t.i.d]).
34
 Although stool potassium levels generally increased and urinary potassium 
levels decreased with increasing total daily RDX7675 dose over the 4-day period, a wider 
RDX7675 dose range and/or a larger number of participants would likely be required to 
establish a dose–response relationship in healthy volunteers. Similar levels of potassium 
excretion were observed using q.d., b.i.d., and t.i.d. dosing of the same 13.7 g total daily 
RDX7675 dose, suggesting that q.d. dosing of RDX7675 will be appropriate for future 
clinical studies. 
 
Stool sodium and calcium excretion generally increased from baseline with RDX7675 across 
the dosing regimens, in line with a propensity of polystyrene sulfonate to bind sodium and 
calcium; there were no consistent trends in stool magnesium or phosphorus excretion. In 
general, there were increases from baseline in stool frequency and stool weight following 
dosing with RDX7675, and no overall trends in stool consistency or ease of passage. 
 
RDX7675 was generally well tolerated during repeated dosing over 4 days, with a low 
incidence of AEs. The most frequently reported AEs judged by the study investigator to be 
related to treatment were gastrointestinal in nature, most commonly abdominal pain and 
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constipation. The incidence of these treatment-related AEs was highest at the highest 
RDX7675 doses, with few treatment-related AEs in the lowest dose cohorts. There were no 
serious or severe AEs. 
 
This study was not designed to compare the pharmacodynamic effects of RDX7675 and SPS, 
and the small number of volunteers given SPS (three per dose cohort) limits the power of any 
comparisons between RDX7675 and SPS. However, it was considered important to assess the 
relative safety and tolerability of the two compounds. The study was conducted open-label as 
the formulations of RDX7675 and SPS used had very different consistencies, and hence it 
was not practical to blind volunteers to study drug assignment. 
 
The efficacy and safety data obtained from this study, together with the results of a 
palatability study showing improved acceptability of various oral formulations of RDX7675 
over SPS,
26
 warrant the continued development of RDX7675 as a q.d. treatment for patients 
with hyperkalemia. Q.d. dosing, being more convenient for patients than taking medication 
multiple times per day, can be expected to result in improved compliance with RDX7675 
compared with b.i.d. or t.i.d. regimens. A phase 3 clinical trial is planned, enrolling patients 
taking RAAS inhibitors and/or mineralocorticoid receptor antagonists and evaluating 
RDX7675 10 g q.d. as a starting dose, similar to the q.d. dose investigated in the present 
phase 1 study. A trial evaluating the time to onset of action of RDX7675 in patients with 
hyperkalemia, together with safety and efficacy, is also planned, which will assess 10 g, 20 g, 
and 30 g q.d. doses. This is a similar total daily dose range to that investigated in the present 
study, which was generally well tolerated. It is hoped that RDX7675 will address the unmet 
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needs of patients with chronic hyperkalemia by proving to be an effective and well-tolerated 
therapy that is suitable for long-term use. 
Conclusions 
In healthy volunteers, repeated oral dosing with RDX7675 over 4 days reduced absorption of 
potassium, as shown by increases in stool potassium with concomitant reductions in urinary 
potassium. Similar levels of potassium excretion were observed using q.d., b.i.d., and t.i.d. 
dosing of a 13.7 g total daily RDX7675 dose, supporting q.d. dosing in future clinical studies. 
RDX7675 was generally well tolerated, with few AEs reported. These data support the 
further clinical development of RDX7675 as a novel treatment for patients with 
hyperkalemia.  
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4.4 g b.i.d. 4.4 g t.i.d. 6.7 g b.i.d. 13.3 g q.d. 8.9 g t.i.d. 13.3 g b.i.d. 




8.9 g 13.3 g 13.3 g 13.3 g 26.7 g 26.7 g 
Cohort order of 
enrollment 
4 1 3 5 2 6 
a
Mass of agent taken. 
b
Active dose administered (after adjustment for counter-exchange ion content). 
b.i.d., twice daily; q.d., once daily; SPS, sodium polystyrene sulfonate; t.i.d., three times daily. 
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Table 2. Demographics and Baseline Characteristics of the Study Volunteers 
 RDX7675 
(N = 73) 
SPS 
(N = 18) 
Age, years  36.5 (13.5) 39.4 (14.9) 
Height, cm 170.2 (9.7) 171.9 (8.0) 
Weight, kg 73.1 (12.7) 75.5 (10.9) 
BMI, kg/m
2
 25.1 (3.4) 25.5 (3.0) 
White, n (%) 65 (89.0) 14 (77.8) 
Male, n (%) 35 (47.9) 10 (55.6) 
Data are mean (standard deviation) unless otherwise stated. 
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Table 3. Daily Excretion of Non-Potassium Electrolytes in Stool in Healthy Volunteers 
Given RDX7675 for 4 Days 
  RDX7675 
4.6 g b.i.d. 4.6 g t.i.d. 6.9 g b.i.d. 13.7 g q.d. 9.2 g t.i.d. 13.7 g b.i.d. 
  (n = 12) (n = 12) (n = 12) (n = 12) (n = 12) (n = 12) 
Sodium, mg       
Baseline  24 (43) 44 (50) 24 (18) 13 (14) 16 (16) 20 (23) 
Day 4 65 (86) 315 (297) 152 (126) 111 (73) 318 (268) 349 (378) 
Calcium, mg       
Baseline  239 (288) 407 (187) 423 (242) 314 (219) 331 (201) 331 (242) 
Day 4 625 (447) 1093 (585) 979 (338) 879 (400) 726 (454) 770 (626) 
Phosphorus, mg       
Baseline  335 (384) 532 (246) 604 (312) 389 (280) 502 (308) 479 (307) 
Day 4 606 (460) 805 (435) 792 (283) 644 (375) 370 (238) 451 (404) 
Magnesium, mg       
Baseline  56 (56) 96 (47) 109 (55) 69 (54) 85 (57) 77 (47) 
Day 4 102 (77) 133 (70) 128 (49) 113 (58) 52 (34) 62 (58) 
Data are mean (standard deviation). 
Baseline values are the mean for days –2 and –1. 
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Table 4. Daily Stool Parameters of Healthy Volunteers Given RDX7675 for 4 Days 
  RDX7675 
4.6 g b.i.d. 
(n = 12) 
4.6 g t.i.d. 
(n = 12) 
6.9 g b.i.d.  
(n = 12) 
13.7 g q.d.  
(n = 12) 
9.2 g t.i.d.  
(n = 12) 
13.7 g b.i.d.  
(n = 12) 
Daily stool frequency,  
bowel movements/day 
Baseline 1.0 (0.9) 1.0 (0.4) 1.2 (0.6) 1.0 (0.5) 1.0 (0.3) 1.2 (1.1) 
Day 4 1.3 (0.8) 1.4 (0.7) 1.5 (0.7) 1.3 (0.6) 1.4 (0.7) 1.6 (1.2) 
Daily stool consistency,  
BSFS score
a 
Baseline 3.7 (0.7) 3.6 (0.7) 4.0 (1.2) 2.7 (1.4) 2.8 (1.1) 3.1 (1.3) 
Day 4 4.6 (0.9) 4.0 (0.7) 3.9 (1.2) 3.9 (1.5) 2.3 (1.3) 2.8 (1.5) 
Ease of passage
b 
Baseline 3.6 (0.4) 4.0 (0.4) 3.7 (0.9) 3.8 (0.3) 3.8 (0.4) 3.7 (0.4) 
Day 4 4.0 (0.5) 3.9 (0.3) 3.6 (1.0) 4.0 (0.0) 3.4 (0.5) 3.6 (0.5) 
Daily stool weight, g/day 
Baseline 70 (88) 123 (81) 140 (69) 71 (59) 77 (44) 91 (55) 
Day 4 139 (101) 274 (158) 324 (125) 161 (73) 136 (78) 151 (152) 
Data are mean (standard deviation). Baseline values are the mean for days –2 and –1. 
a
BSFS: 1 = hard lumps; 2 = lumpy sausage; 3 = cracked sausage; 4 = smooth sausage; 5 = soft lumps; 
6 = mushy; 7 = watery. 
b
Ease of passage categories: 1 = manual disimpaction; 2 = enema needed; 3 = straining needed; 4 = 
normal; 5 = urgent without pain; 6 = urgent with pain; 7 = incontinent. 
b.i.d., twice daily; BSFS, Bristol Stool Form Scale; q.d., once daily; t.i.d., three times daily.  
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Table 5. Summary of Adverse Events in Healthy Volunteers Given RDX7675 or SPS for 4 
Days 
  RDX7675 
4.6 g b.i.d. 4.6 g t.i.d. 6.9 g b.i.d. 13.7 g q.d. 9.2 g t.i.d. 13.7 g b.i.d. 
  (n = 12) (n = 12) (n = 12) (n = 13
a
) (n = 12) (n = 12) 
Any AE
b
 2 4 1 2 10 5 
Treatment-related AE 1 2 0 0 8 4 
Serious AE 0 0 0 0 0 0 
Discontinuation due to 
AE 
0 0 0 0 1 0 
Specific treatment-related AEs
c
      
Cardiac disorders       
Palpitations 0 1 0 0 1 0 
Gastrointestinal 
disorders 
      
Abdominal 
discomfort 
0 1 0 0 0 0 
Abdominal 
distension 
0 0 0 0 0 1 
Abdominal pain 1 1 0 0 3 2 
Constipation 0 0 0 0 4 0 
Diarrhea 1 0 0 0 0 0 
Nausea 0 0 0 0 3 0 
Vomiting 0 0 0 0 1 1 
Metabolism and 
nutrition 
      
Decreased appetite 0 0 0 0 0 1 
Musculoskeletal and 
connective tissue 
      
Back pain 0 0 0 0 1 0 
 
  SPS 
4.4 g b.i.d. 4.4 g t.i.d. 6.7 g b.i.d. 13.3 g q.d. 8.9 g t.i.d. 13.3 g b.i.d. 
  (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) 
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Any AE
b
 1 0 2 1 1 1 
Treatment-related AE 0 0 1 0 1 1 
Serious AE 0 0 0 0 0 0 
Discontinuation due to 
AE 
0 0 0 0 0 0 
Specific treatment-related AEs
c
      
Gastrointestinal 
disorders 
      
Abdominal pain 0 0 0 0 1 0 
Constipation 0 0 0 0 1 0 
Flatulence 0 0 1 0 0 0 
Skin and subcutaneous 
tissue 
      
Rash erythematous 0 0 0 0 0 1 
a
Includes one volunteer who withdrew and was replaced. 
b
Data are number of volunteers. 
c
Data are number of AEs. 





This article is protected by copyright. All rights reserved. 
Figure Legends 
 
Figure 1. Change in daily potassium excretion from baseline in (A) stool and (B) urine over 
4 days in healthy volunteers given RDX7675. 
Data are mean ± standard deviation (n = 12 for each cohort, except: day 1 urinary potassium, 
4.6 g b.i.d., n = 11; day 1 urinary potassium, 13.7 g b.i.d., n = 11; day 2 stool potassium, 4.6 g 
b.i.d., n = 11). 
Baseline values are mean (standard deviation) over days –2 and –1.  
b.i.d., twice daily; q.d., once daily; t.i.d., three times daily. 
 
 
